Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Revelation Biosciences ( (REVB) ) is now available.
Revelation Biosciences, Inc. announced a 1-for-3 reverse stock split effective July 7, 2025, following approval at its Special Meeting of Stockholders on June 23, 2025. The move aims to increase the market price per share to comply with Nasdaq’s minimum bid requirements. Additionally, the company is nearing completion of enrollment for its PRIME Phase 1b clinical study of Gemini in CKD patients, with topline data expected soon.
The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of diseases using its proprietary formulation Gemini. The company is involved in multiple ongoing programs evaluating Gemini for various applications, including prevention of post-surgical infection, acute kidney injury, and treatment of chronic kidney disease.
Average Trading Volume: 379,020
Technical Sentiment Signal: Sell
Current Market Cap: $1.75M
For a thorough assessment of REVB stock, go to TipRanks’ Stock Analysis page.